Patents Examined by Traviss C. McIntosh, III
  • Uracyl spirooxetane nucleosides
    Patent number: 10774106
    Abstract: The present invention relates to compounds of the formula I: including any possible stereoisomers thereof, wherein R9 has the meaning as defined herein, or a pharmaceutically acceptable salt or solvate thereof. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HCV inhibitors, in HCV therapy.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: September 15, 2020
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Ioannis Nicolaos Houpis, Tim Hugo Maria Jonckers, Pierre Jean-Marie Bernard Raboisson, Abdellah Tahri
  • Galactoside inhibitor of galectins
    Patent number: 10774102
    Abstract: An embodiment of the present invention relates to a compound of the general formula. The compound of formula is suitable for use in a method for treating a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human. Furthermore an embodiment of the present invention concerns a method for treatment of a disorder relating to the binding of a galectin, such as galectin-3 to a ligand in a mammal, such as a human.
    Type: Grant
    Filed: January 28, 2016
    Date of Patent: September 15, 2020
    Assignee: Galecto Biotech AB
    Inventors: Thomas Brimert, Richard Johnsson, Hakon Leffler, Ulf Nilsson, Fredrik Zetterberg
  • E-selectin antagonist compounds, compositions, and methods of use
    Patent number: 10766916
    Abstract: Methods and compositions using E-selectin antagonists are provided for the treatment and prevention of diseases and disorders treatable by inhibiting binding of E-selectin to an E-selectin ligand. Described herein are E-selectin antagonists including, for example, glycomimetic compounds, antibodies, aptamers and peptides that are useful in methods for treatment of cancers, and treatment and prevention of metastasis, inhibiting infiltration of the cancer cells into bone marrow, reducing or inhibiting adhesion of the cancer cells to endothelial cells including cells in bone marrow, and inhibiting thrombus formation.
    Type: Grant
    Filed: November 20, 2019
    Date of Patent: September 8, 2020
    Assignee: GLYCOMIMETICS, INC.
    Inventors: John L. Magnani, Arun K. Sarkar, Myung-Gi Baek, Frank E. Anderson, III, Yanhong Li
  • TLR4 agonists and compositions thereof and their use in the treatment of cancer
    Patent number: 10765690
    Abstract: Disclosed is a TLR4 agonist alone or in combination with an anti-cancer agent and pharmaceutical compositions thereof, uses thereof, and methods of treatment comprising administering said composition or combination, including uses in cancer.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: September 8, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Christopher W. Cluff, Hua-Xin Gao
  • Maribavir isomers, compositions, methods of making and methods of using
    Patent number: 10765692
    Abstract: The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: September 8, 2020
    Assignee: Shire Viropharma Incorporated
    Inventor: John D. Peabody, III
  • Water soluble nitric oxide-releasing polyglucosamines and uses thereof
    Patent number: 10759877
    Abstract: The presently disclosed subject matter provides nitric oxide-releasing polysaccharides and oligosaccharides, in particular, polyglucosamines, and their use in biomedical and pharmaceutical applications. More particularly, in some embodiments, the presently disclosed subject matter provides nitric oxide-releasing polysaccharides and oligosaccharides that release nitric oxide in a controlled and targeted manner, thereby prolonging the therapeutic effects of nitric oxide and improving the specificity of nitric oxide delivery to targeted cells and/or tissues.
    Type: Grant
    Filed: December 8, 2017
    Date of Patent: September 1, 2020
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: Mark H. Schoenfisch, Yuan Lu
  • Methods and compositions for treating hepatitis C virus
    Patent number: 10758557
    Abstract: A method and composition for treating a host infected with hepatitis C comprising administering an effective hepatitis C treatment amount of a described 1?, 2? or 3?-modified nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: September 1, 2020
    Assignees: Idenix Pharmaceuticals LLC, Universita degli Studi di Cagliari
    Inventors: Jean-Pierre Sommadossi, Paolo La Colla
  • Mannose-derived antagonists of FimH useful for treating disease
    Patent number: 10738070
    Abstract: The present invention relates to mannoside derivative compounds useful as inhibitors of FimH and methods for the treatment or prevention of urinary tract infection.
    Type: Grant
    Filed: March 23, 2017
    Date of Patent: August 11, 2020
    Assignee: Fimbrion Therapeutics, Inc.
    Inventors: James W. Janetka, Laurel Mydock-McGrane
  • Catecholamine prodrugs for use in the treatment of Parkinson's disease
    Patent number: 10729710
    Abstract: The present invention provides compounds of formula (I) that are prodrugs of catecholamine for use in treatment of neurodegenerative diseases and disorders. The present invention also provides pharmaceutical compositions comprising compounds of the invention and methods of treating neurodegenerative or neuropsychiatric diseases and disorders using the compounds of the invention, in particular Parkinson's disease.
    Type: Grant
    Filed: November 23, 2018
    Date of Patent: August 4, 2020
    Assignee: H. Lundbeck A/S
    Inventors: Klaus Gjervig Jensen, Lisbet Kværnø, Morten Jørgensen, Martin Juhl
  • Calicheamicin-antibody-drug conjugates and methods of use
    Patent number: 10730900
    Abstract: The invention relates generally to a calicheamicin molecule activated with a leaving group. The invention further relates generally to an antibody-drug conjugate comprising an antibody directly conjugated by a disulfide to one or more calicheamicin molecules.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: August 4, 2020
    Assignee: Genentech, Inc.
    Inventor: Thomas Pillow
  • Adenosine analogs as methyltransferase inhibitors for treating cancer
    Patent number: 10730903
    Abstract: Compounds having methyltransferase inhibitory activity are disclosed. The compounds have the structures The compounds disclosed are useful in the treatment of cancer and similar diseases associated with inappropriate methyltransferase activity.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: August 4, 2020
    Assignee: MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Minkui Luo, Xiaochuan Cai, Ke Wang, Junyi Wang
  • Compounds
    Patent number: 10730907
    Abstract: A compound of Formula (I) wherein Y1, Y2, X1, X2, R1, R2, R3, R4, R5, R6, R8, and R9 are as defined herein; and pharmaceutically acceptable salts and tautomers thereof, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments, in the treatment of diseases in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.
    Type: Grant
    Filed: July 26, 2019
    Date of Patent: August 4, 2020
    Assignee: GlaxoSmithKline Intellectual Property Development Limited
    Inventors: Jerry Adams, Yiqian Lian
  • 2?,4?-bridged nucleosides for HCV infection
    Patent number: 10723754
    Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 2?,4?-bridged nucleosides which display remarkable efficacy and bioavailability for the treatment of, for example, HCV infection in a human. In certain embodiments, the 2?,4?-bridged nucleosides are of Formula 3001: or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, where PD, B, W, X, RA, RB, RC and RD are as described herein.
    Type: Grant
    Filed: October 21, 2013
    Date of Patent: July 28, 2020
    Assignee: Idenix Pharmaceuticals LLC
    Inventors: Benjamin Alexander Mayes, Adel M. Moussa, Alistair James Stewart
  • DNA polymerase beta inhibitors
    Patent number: 10711027
    Abstract: Methods and compounds are disclosed for irreversibly inhibiting a DNA repair enzyme that possesses lyase activity.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: July 14, 2020
    Assignee: The Johns Hopkins University
    Inventors: Marc M. Greenberg, Rakesh Paul
  • Beta-d-2?-deoxy-2?-alpha-fluoro-2?-beta-c-substituted-4?fluoro-n6-substituted-6-amino-2-substituted purine nucleotides for the treatment of hepatitis c virus infection
    Patent number: 10711029
    Abstract: Compounds of Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX and Formula X that are highly active against the HCV virus when administered in an effective amount to a host in need thereof. The host can be a human or any animal that carries the viral infection. Methods of treating a subject suffering from a condition related to viral infections are also provided.
    Type: Grant
    Filed: July 14, 2017
    Date of Patent: July 14, 2020
    Assignee: ATEA Pharmaceuticals, Inc.
    Inventors: Jean-Pierre Sommadossi, Adel Moussa
  • Gemcitabine ProTide hypoxia-activated prodrug and application thereof
    Patent number: 10709725
    Abstract: A gemcitabine ProTide hypoxic-activated prodrug and a use thereof in the preparation of a medicament for treating tumors. The general structural formula thereof is formula (A), wherein: one of R1 and R2 is a hypoxic-activated group of —C(R3R4)ArNO2, and the other is an alkyl group of 1 to 6 carbon atoms, a phenyl group or —CH2Ar, wherein R3 and R4 are —H or a methyl group, and —Ar is an aromatic ring compound. The gemcitabine ProTide hypoxic-activated prodrug described in the present invention has a stronger cytotoxicity under a hypoxic condition, has excellent anti-tumor effects and is very safe; the present invention can be used along with other anti-tumor drugs to exert a better anti-tumor activity, and can be used in the preparation of a medicament for treating tumors.
    Type: Grant
    Filed: August 3, 2017
    Date of Patent: July 14, 2020
    Assignee: JIANGSU QIANZHIKANG BIOLOGICAL MEDICINE SCIENCE AND TECHNOLOGY CO., LTD
    Inventor: Fei Li
  • Methods for treating filoviridae virus infections
    Patent number: 10695357
    Abstract: Provided are compounds, methods, and pharmaceutical compositions for treating Filoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula IV: The compounds, compositions, and methods provided are particularly useful for the treatment of Marburg virus, Ebola virus and Cueva virus infections.
    Type: Grant
    Filed: February 12, 2019
    Date of Patent: June 30, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Byoung Kwon Chun, Michael O'Neil Hanrahan Clarke, Edward Doerffler, Hon Chung Hui, Robert Jordan, Richard L. Mackman, Jay P. Parrish, Adrian S. Ray, Dustin Siegel
  • Methods for treating arenaviridae and coronaviridae virus infections
    Patent number: 10695361
    Abstract: Provided are methods for treating Arenaviridae and Coronaviridae virus infections by administering nucleosides and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Lassa virus and Junin virus infections.
    Type: Grant
    Filed: February 1, 2019
    Date of Patent: June 30, 2020
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Michael O'Neil Hanrahan Clarke, Joy Yang Feng, Robert Jordan, Richard L. Mackman, Adrian S. Ray, Dustin Siegel
  • Nicotinamide riboside compositions for topical use in treating skin conditions
    Patent number: 10688118
    Abstract: Compositions containing nicotinamide riboside (NR) are provided. NR containing compositions are used in the care or treatment of skin and skin conditions. In some embodiments, the invention relates to pharmaceutical compositions and cosmetic compositions containing nicotinamide riboside. In further embodiments, the invention relates to methods of using nicotinamide riboside to promote the increase of intracellular levels of nicotinamide adenine dinucleotide (NAD+) in cells and tissues for improving cell and tissue survival. A method of treating signs or symptoms of aging or skin wrinkles in an individual is provided, comprising topically administering to the individual in need of such treatment an effective amount of the compound nicotinamide riboside, or salts thereof.
    Type: Grant
    Filed: October 30, 2014
    Date of Patent: June 23, 2020
    Assignee: ChromaDex Inc.
    Inventors: Ann Deren-Lewis, Troy Rhonemus
  • Substituted nucleosides, nucleotides and analogs thereof
    Patent number: 10683320
    Abstract: Disclosed herein are nucleotide analogs, methods of synthesizing nucleotide analogs and methods of treating diseases and/or conditions such as a HCV infection with one or more nucleotide analogs.
    Type: Grant
    Filed: November 28, 2018
    Date of Patent: June 16, 2020
    Assignee: Janssen BioPharma, Inc.
    Inventors: Leonid Beigelman, Guangyi Wang, David Bernard Smith